LONDON: Scancell Holdings plc (AIM: SCLP), a developer of cancer immunotherapies, has appointed Dr. Phil L’Huillier as the new Chief Executive Officer, effective November 18, 2024. Dr. L’Huillier, previously CEO of CatalYm GmbH, brings extensive experience in expanding investor bases and progressing clinical studies. Professor Lindy Durrant, the current CEO, will remain in her role…
All posts tagged Scancell Holdings
Scancell initiates development of novel DNA vaccine against COVID-19
LONDON: Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, in collaboration with scientists in the newly established…